Literature DB >> 21187470

All-trans retinoic acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent manner.

Michael Karsy1, Ladislau Albert, Michael E Tobias, Raj Murali, Meena Jhanwar-Uniyal.   

Abstract

Glioblastoma multiforme (GBM), a grade IV glioma, appears to harbor therapy-resistant cancer stem cells (CSCs) that are the major cause of recurrence. All-trans retinoic acid (ATRA), a derivative of retinoid, is capable of differentiating a variety of stem cells, as well as normal neural progenitor cells, and down-regulates expression of the stem cell marker nestin. This study investigated the effects of ATRA on differentiation, proliferation, self-renewal, and signaling pathways of CSCs in GBM. CSCs differentiated into glial and neuronal lineages at low concentrations of ATRA (10 μM). Proliferation and self renewal of neurospheres were reduced following ATRA, although ATRA induced apopotsis at higher (40 μM) concentrations. Analysis of mitogen-activated protein kinase signaling pathways, specifically extracellular signal-regulated kinases (ERK1/2), showed that ATRA-induced alterations in ERK1/2 were associated with regulation of differentiation, proliferation and apoptosis. These results emphasize that low doses of ATRA may have therapeutic potential by differentiating GBM CSCs and rendering them sensitive to targeted therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187470

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  36 in total

1.  Synchronous glioblastoma and medulloblastoma in a child with mismatch repair mutation.

Authors:  Nisreen Amayiri; Maysa Al-Hussaini; Maisa Swaidan; Imad Jaradat; Monther Qandeel; Uri Tabori; Cynthia Hawkins; Awni Musharbash; Khulood Alsaad; Eric Bouffet
Journal:  Childs Nerv Syst       Date:  2015-08-21       Impact factor: 1.475

2.  3D Mathematical Modeling of Glioblastoma Suggests That Transdifferentiated Vascular Endothelial Cells Mediate Resistance to Current Standard-of-Care Therapy.

Authors:  Huaming Yan; Mónica Romero-López; Lesly I Benitez; Kaijun Di; Hermann B Frieboes; Christopher C W Hughes; Daniela A Bota; John S Lowengrub
Journal:  Cancer Res       Date:  2017-05-23       Impact factor: 12.701

3.  The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma.

Authors:  Michael Karsy; Ladislau Albert; Raj Murali; Meena Jhanwar-Uniyal
Journal:  Tumour Biol       Date:  2014-01-08

Review 4.  Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.

Authors:  Arshawn Sami; Michael Karsy
Journal:  Tumour Biol       Date:  2013-04-30

5.  Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme.

Authors:  Michael Karsy; Erol Arslan; Fred Moy
Journal:  Genes Cancer       Date:  2012-01

Review 6.  Role of OCT4 in cancer stem-like cells and chemotherapy resistance.

Authors:  Ismail S Mohiuddin; Sung-Jen Wei; Min H Kang
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-03-21       Impact factor: 5.187

Review 7.  Stem cells in gastric cancer.

Authors:  Yue Zhao; Fei Feng; Yong-Ning Zhou
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

8.  Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.

Authors:  Jin-Chul Heo; Tae-Hoon Jung; Sungjin Lee; Hyun Young Kim; Gildon Choi; Myungeun Jung; Daeyoung Jung; Heung Kyoung Lee; Jung-Ok Lee; Ji-Hwan Park; Daehee Hwang; Ho Jun Seol; Heeyeong Cho
Journal:  Clin Exp Metastasis       Date:  2016-03-08       Impact factor: 5.150

Review 9.  Therapeutic strategies targeting cancer stem cells.

Authors:  Xiaoyan Ning; Jianchang Shu; Yiqi Du; Qiwen Ben; Zhaoshen Li
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

Review 10.  Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.

Authors:  Bryant England; Tiangui Huang; Michael Karsy
Journal:  Tumour Biol       Date:  2013-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.